{"disease":{"id":"hepatitis-c-virus-hcv","name":"hepatitis c virus hcv"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07388979","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":7500,"lead_sponsor_name":"Gardiens de Vies","has_results":false},{"nct_id":"NCT02219490","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1596,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03341871","title":"Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6","phase":"","overall_status":"COMPLETED","enrollment_count":1095,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02167945","title":"A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":615,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07122219","title":"Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons","phase":"NA","overall_status":"RECRUITING","enrollment_count":548,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT03222583","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":546,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03201718","title":"A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":505,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03089944","title":"A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":343,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07433985","title":"California MEPS Hub","phase":"NA","overall_status":"RECRUITING","enrollment_count":318,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT04903626","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05904470","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03212521","title":"Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03235349","title":"Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03067129","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03111108","title":"Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02609659","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02517528","title":"ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03069365","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT03219216","title":"A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04352309","title":"Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04189627","title":"A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation","phase":"","overall_status":"COMPLETED","enrollment_count":99,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04366973","title":"A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers","phase":"","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02966795","title":"A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04214028","title":"A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04577482","title":"Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response","phase":"","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03002818","title":"Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","phase":"","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02487199","title":"Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT04513899","title":"Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults","phase":"NA","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University of California, Irvine","has_results":true},{"nct_id":"NCT04019717","title":"Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Atea Pharmaceuticals, Inc.","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}